Ucgul Ahmet Yucel, Özdek Şengül
Training and Research Hospital, Ahi Evran University, Kırşehir, Turkey.
Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey.
Semin Ophthalmol. 2025 Aug;40(6):458-473. doi: 10.1080/08820538.2024.2447965. Epub 2024 Dec 30.
Coats' disease, first described by George Coats in 1908, is a rare ocular disorder primarily affecting young males, often unilaterally. It is characterized by retinal telangiectasia, aneurysms, and exudation, which, in severe cases, can lead to blindness, painful red eye, or ocular atrophy, particularly with early childhood onset. Over the last century, advancements have been made in understanding its natural history, morphology, incidence, and clinical manifestations, showing a male predominance without significant ethnic disparities. This review aims to provide a comprehensive overview of Coats' disease, focusing on its pathogenesis, clinical presentation, diagnostic methods, and management strategies.
The pathogenesis of Coats' Disease is multifactorial, involving inflammatory, vascular, and potentially genetic components. Early theories suggested inflammation as the primary cause, but modern research highlights the role of vascular endothelial growth factor (VEGF), where ischemic retinal areas elevate VEGF levels, promoting angiogenesis and impairing the blood-retinal barrier. Clinically, the disease is asymptomatic in early stages but progresses to symptoms like reduced visual acuity, strabismus, and leukocoria, typically within the first decade of life. Diagnostic methods include fundus fluorescein angiography, optical coherence tomography (OCT), and OCT angiography (OCTA), with recent studies identifying reduced blood flow density in capillary networks. Management ranges from intravitreal anti-VEGF agents and steroids to surgical options like pars plana vitrectomy and transscleral drainage, with additional techniques such as laser photocoagulation and cryotherapy proving effective in advanced stages.
The prognosis of Coats' Disease heavily depends on the stage of disease at presentation. Early detection and intervention can preserve vision, but advanced stages often result in poor outcomes. Factors such as younger age at presentation, advanced stage, and severe manifestations are associated with more aggressive progression and poorer prognosis. This review highlights the importance of early diagnosis and a multifaceted management approach, emphasizing the need for further research into its pathophysiology and innovative treatment strategies to improve patient outcomes.
科茨病由乔治·科茨于1908年首次描述,是一种罕见的眼部疾病,主要影响年轻男性,通常为单侧发病。其特征为视网膜毛细血管扩张、动脉瘤和渗出,在严重情况下可导致失明、眼红疼痛或眼球萎缩,尤其是在儿童早期发病时。在过去的一个世纪里,人们对其自然史、形态学、发病率和临床表现的认识取得了进展,显示男性占主导地位,且无明显种族差异。本综述旨在全面概述科茨病,重点关注其发病机制、临床表现、诊断方法和管理策略。
科茨病的发病机制是多因素的,涉及炎症、血管和潜在的遗传因素。早期理论认为炎症是主要原因,但现代研究强调血管内皮生长因子(VEGF)的作用,即缺血性视网膜区域会升高VEGF水平,促进血管生成并损害血视网膜屏障。临床上,该病在早期无症状,但通常在生命的第一个十年内进展为视力下降、斜视和白瞳症等症状。诊断方法包括眼底荧光血管造影、光学相干断层扫描(OCT)和OCT血管造影(OCTA),最近的研究发现毛细血管网络中的血流密度降低。管理方法包括玻璃体内注射抗VEGF药物和类固醇,以及如玻璃体切除术和平巩膜引流等手术选择,此外激光光凝和冷冻疗法等技术在晚期也被证明有效。
科茨病的预后很大程度上取决于发病时的疾病阶段。早期发现和干预可以保留视力,但晚期往往导致不良后果。发病时年龄较小、疾病晚期和严重表现等因素与更具侵袭性的进展和更差的预后相关。本综述强调了早期诊断和多方面管理方法的重要性,强调需要进一步研究其病理生理学和创新治疗策略以改善患者预后。